

result	NC_	Score	Query	Match length	DB	ID	Description
1	483	100.0	483	19	NAV41548		Human soluble tumour necrosis factor
2	483	100.0	483	19	NAV19801		Soluble tumour necrosis factor
3	483	100.0	483	20	NAV81732		Tumour necrosis factor
4	483	100.0	483	22	AAC83945		Human 30 kDa TNF- α
5	483	100.0	1301	18	AAQ194022		cDNA for TBP (20-19 kDa)
6	483	100.0	1334	11	AAQ06282		Plasmid Tumour necrosis factor
7	483	100.0	1368	14	AAQ49432		Lamellar-derived TNF
8	483	100.0	1488	21	AAQ51065		Human TNF- α coding
9	483	100.0	1478	20	AAK58150		Cadd-t fusion polypeptide
10	483	100.0	2062	12	AAQ26473		TNF- α binding protein
11	483	100.0	2062	13	AAQ24440		Encodes TNF- α

A1.1 GNMENI S

RESULT		AAV4.54.8	
10	AAV4.54.8 standard	cDNA:	4.63 kB
XX			
AC	AAV4.54.8;		
XX			
11	267-SER-1775 (AAV4.54.8)		
XX			
12	Human-specific human receptor type 1.		
XX			
KW	Human, tumour necrosis factor, IgG, IgM receptor type 1.		
GW	267-Lysine-279-Lysine, trichedrol, SHP binding protein;		
GW	267-Lysine-279-Lysine, trichedrol, SHP binding protein; se-		
GW	267-Lysine-279-Lysine, trichedrol, SHP binding protein; se-		

is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed. N_{ch} is derived by analysis of the total score distribution.

✓ tag = a product - human soluble TNF receptor type I

4.83	1.60	0	1.48 ^a	2.1	AAAGAGAG	Human TNF β
4.83	1.60	0	1.47 ^b	2.0	AAAGS8150	CdC fusion pO
4.83	1.60	0	2.05 ^b	1.4	AAACGAGT	TNF- α bind
4.83	1.60	0	2.05 ^b	1.4	AAACGAGT	TNF- α bind

MARK IES

XX	W09824463-A2.
PN	
XX	
PD	11-JUN-1968.
XX	
PF	08-DEC-1997;
XX	07W-05222745.
PF	09-JUL-1997;
PF	06-DEC-1996;
PF	23-JAN-1997;
PF	07-FEB-1997;
XX	07W-05222745.
PA	(AM) 1 AM 191900.

nerosis factor (TNF). The products of the invention have anti-inflammatory and antimicrobial activity. (I) and (IIa) are used (i) to treat diseases in which TNF is involved (e.g. septic shock, autoimmune glomerulonephritis, cerebral malaria, immune responses and inflammation), (ii) to purify TNF, (iii) to identify TNF antagonists and (iv) for diagnostic determination of TNF in body fluids. Antibodies raised against (I) are used for affinity purification of (II). This sequence encodes a tumour necrosis factor binding protein described in the method of the invention.

XX *Journal of Health Politics, Policy and Law* 30(1)

Search completed: April 24, 2002, 02:28:29
Job time: 3407 sec